Enanta Pharmaceuticals is a research and development (R&D) biotechnology company in Massachusetts, United States. Their primary objective is to conduct research in the field of liver diseases and viral infections.
They use powerful chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Their R&D is primarily focused on three disease targets:
- Hepatitis B Virus (HBV)
- PBC and Respiratory Syncytial Virus (RSV)
- Non-alcoholic SteatoHepatitis (NASH)
Enanta has discovered a novel protease-inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes, which was originally designed for use against the Hepatitis-C Virus (HCV).
Enanta has discovered EDP-305, an FXR agonist product candidate for NASH and PBC, currently in Phase 1 clinical development, and has identified a clinical candidate for RSV, EDP-938, now, in preclinical development. They are also developing early-lead candidates for HBV.
